Black Diamond Therapeutics vs Champions Oncology
BDTX and CSBR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDTX and CSBR compare
Black Diamond Therapeutics is the larger company, worth 1.4 times as much as Champions Oncology ($92.5M against $66.5M).
Champions Oncology grew revenue faster over the last twelve months (6.7% versus −100% for Black Diamond Therapeutics).
Champions Oncology scores higher on the StockData Score (9 against 7 for Black Diamond Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDTX | CSBR |
|---|---|---|
| Size and price | ||
| Market cap | $92.5M | $66.5M |
| Share price | $1.61 | $4.78 |
| Change, 1 year | −63.1% | −29.5% |
| Change, 5 years | −77.3% | −49.0% |
| Beta (5Y) | 2.49 | 0.36 |
| Employees | 21 | 214 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.1× |
| P/B | 1.1× (better) | 17.1× |
| EV/EBITDA | – | 216× |
| FCF yield | – | −9.2% |
| Fair value | – | $1.36 |
| Margin of safety | – | −251% |
| Growth | ||
| Revenue growth (TTM) | −100% | 6.7% (better) |
| Revenue growth, 5Y average | – | 7.7% |
| Net income growth (TTM) | −305% | −138% (better) |
| EPS growth (TTM) | −311% | −140% (better) |
| Profitability | ||
| Gross margin | – | 49.8% |
| Operating margin | – | −1.7% |
| Net margin | – | −1.8% |
| FCF margin | – | −10.1% |
| Return on equity | −41.1% | −29.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.92 (better) | 1.03 |
| Altman Z-score | −4.53 | −0.30 (better) |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 61.0% | 42.4% |
| Held by insiders | 9.1% | 30.5% |
| Short interest, % of float | 9.8% | 0.75% |
Go deeper
- BDTX stock overview
- BDTX income statement
- BDTX valuation and score
- CSBR stock overview
- CSBR income statement
- CSBR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.